Zealand Pharma — November 2022
-
CSørensen - Jeg forventer at vi høre noget om at EASE 2 studiet status. Jeg forventer at høre noget om BI 456906 og hvad Boehringer Ingelheim vil videre. Vil også se efter Protagonist Therapeutics milepælsbetaling. Jeg froventer dette bliver positivt.
-
Jeg har ikke noget godt overblik over hvad Boehringer Ingelheim skal betale for at gå ind i fase 3 og det bliver interessant at høre om hvad tidshorisonten er på dette projekt.
-
@exitnu - point for den helgardering
-
kom så ZP
-
Zealand Pharma Announces Financial Results for the First Nine Months of 2022
Financial results for the first nine months of 2022
• Revenue: DKK 80.1 million (DKK 95.1 million in the first nine months of 2021).
• Net operating expenses: DKK -675.7 million (DKK -652.8 million in the first nine months of 2021).
• Net operating result: DKK -596.2 million (DKK -568.7 million in the first nine months of 2021).
• Net financial items: DKK -53.4 million (DKK 21.5 million in the first nine months of 202 -
Zealand Pharma Announces Financial Results for the First Nine Months of 2022
Company announcement No. 51 / 2022 Zealand Pharma Announces Financial Results for the First Nine Months of 2022 Copenhagen, Denmark November 10, 2022 –...
GlobeNewswire News Room (www.globenewswire.com)
-
Financial guidance for 2022
The company will no longer provide guidance on net product revenue, reflecting the completion of the asset purchase agreement for V-Go
with MannKind Corporation and the completion of the global license and development agreement for Zegalogue with Novo Nordisk. -
.... In 2022, Zealand expects revenue from existing license agreements. However, since such revenue is uncertain in terms of size and timing, Zealand does not intend to provide guidance on such revenue.
Net operating expenses in 2022 are expected to be DKK 1,000 million +/-10%*. This is unchanged from our updated guidance issued on March 30, 2022. -
-
Zealand Pharma fastholder forventningerne til regnskabsåret 2022 om nettodriftsomkostninger omkring 1000 mio. kr., mens selskabet har suspenderet forventningerne til produktsalget.
Det fremgår af biotekselskabets regnskab for tredje kvartal af 2022..\˙ MarketWire
-
Upcoming events
• Initiate Phase 1b MAD trial of ZP8396, a long-acting amylin analogue in development for obesity by the end of the fourth quarter 2022.
• Interim Phase 3 data from EASE-SBS 2 and 3 long term extension trials of glepaglutide expected by the end of the fourth quarter 2022, and first quarter of 2023, respectively. -
ser i noget "breaking"?
-
ZEAL - Financial Results for the First Nine Months 2022 https://www.proinvestor.com/boards/107722
-
tak
-
Non event.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind